During the past decade, IU Health Central Indiana Cancer Centers-East conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 30 clinical trials were completed, i.e. on average, 1500% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 13 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "IU Health Central Indiana Cancer Centers-East" #1 sponsor was "National Cancer Institute (NCI)" with 14 trials, followed by "SWOG Cancer Research Network" with 10 trials sponsored, "Radiation Therapy Oncology Group" with 8 trials sponsored, "Alliance for Clinical Trials in Oncology" with 3 trials sponsored and "Aegera Therapeutics" with 3 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "IU Health Central Indiana Cancer Centers-East" #1 collaborator was "National Cancer Institute (NCI)" with 23 trials as a collaborator, "NRG Oncology" with 11 trials as a collaborator, "Radiation Therapy Oncology Group" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Cancer and Leukemia Group B" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "IU Health Central Indiana Cancer Centers-East" are "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (7 trials), "Breast Cancer" (3 trials), "Prostate Cancer" (3 trials) and "Breast Ductal Carcinoma In Situ" (2 trials). Many other conditions were trialed in "IU Health Central Indiana Cancer Centers-East" in a lesser frequency.

Most popular intervention types in "IU Health Central Indiana Cancer Centers-East" are "Drug" (37 trials), "Other" (26 trials), "Radiation" (14 trials), "Biological" (13 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (21 trials), "Quality-of-Life Assessment" (6 trials), "Docetaxel" (5 trials), "Paclitaxel" (4 trials) and "Carboplatin" (3 trials). Other intervention names were less common.

The vast majority of trials in "IU Health Central Indiana Cancer Centers-East" are 33 trials for "All" genders, 6 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "IU Health Central Indiana Cancer Centers-East". undefined are not yet recruiting, 1 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in IU Health Central Indiana Cancer Centers-East, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in IU Health Central Indiana Cancer Centers-East, 3 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".